Mesoblast Limited

OTCPK:MEOB.F Stock Report

Market Cap: US$1.9b

Mesoblast Valuation

Is MEOB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of MEOB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: MEOB.F ($1.7) is trading below our estimate of future cash flow value ($2.67)

Significantly Below Future Cash Flow Value: MEOB.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEOB.F?

Key metric: As MEOB.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MEOB.F. This is calculated by dividing MEOB.F's market cap by their current revenue.
What is MEOB.F's PS Ratio?
PS Ratio28.5x
SalesUS$65.38m
Market CapUS$1.87b

Price to Sales Ratio vs Peers

How does MEOB.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MEOB.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average22.3x
STOK Stoke Therapeutics
63.4x56.28%US$2.0b
ARQT Arcutis Biotherapeutics
6.4x18.97%US$2.6b
IDYA IDEAYA Biosciences
11x42.08%US$2.5b
ANAB AnaptysBio
8.3x21.98%US$2.0b
MEOB.F Mesoblast
28.5x45.11%US$2.6b

Price-To-Sales vs Peers: MEOB.F is expensive based on its Price-To-Sales Ratio (28.5x) compared to the peer average (22.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does MEOB.F's PS Ratio compare vs other companies in the US Biotechs Industry?

123 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.9x2.40%US$28.56b
INCY Incyte
3.7x-2.09%US$19.69b
BMRN BioMarin Pharmaceutical
3.1x10.25%US$10.45b
ALKS Alkermes
3.8x9.88%US$5.83b
MEOB.F 28.5xIndustry Avg. 9.7xNo. of Companies123PS01632486480+
123 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MEOB.F is expensive based on its Price-To-Sales Ratio (28.5x) compared to the US Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is MEOB.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEOB.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio28.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MEOB.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEOB.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$2.73
0%
21.13%US$3.39US$2.02n/a4
May ’27US$1.70
US$2.73
+60.83%
21.13%US$3.39US$2.02n/a4
Apr ’27US$1.60
US$2.76
+72.65%
17.67%US$3.34US$2.27n/a4
Mar ’27n/a
US$2.79
0%
17.03%US$3.35US$2.28n/a4
Feb ’27n/a
US$2.78
0%
16.71%US$3.32US$2.19n/a4
Jan ’27n/a
US$2.51
0%
16.69%US$3.13US$2.06n/a4
Dec ’26n/a
US$2.44
0%
16.69%US$3.05US$2.01n/a4
Nov ’26US$1.97
US$2.40
+22.27%
18.84%US$3.05US$1.95n/a4
Oct ’26n/a
US$2.27
0%
21.81%US$3.07US$1.76n/a4
Sep ’26US$1.51
US$2.28
+51.14%
21.81%US$3.08US$1.77n/a4
Aug ’26US$1.51
US$2.35
+55.65%
23.99%US$3.07US$1.70n/a3
Jul ’26n/a
US$2.24
0%
27.00%US$3.01US$1.53n/a3
Jun ’26US$1.44
US$2.24
+54.82%
27.00%US$3.01US$1.53n/a3
May ’26US$1.44
US$2.24
+55.72%
27.00%US$3.01US$1.53US$1.703
Apr ’26n/a
US$2.41
0%
26.46%US$2.99US$1.52US$1.603
Mar ’26n/a
US$2.55
0%
32.12%US$3.48US$1.49n/a3
Feb ’26n/a
US$2.47
0%
34.33%US$3.52US$1.44n/a3
Jan ’26US$2.20
US$1.94
-11.84%
58.33%US$3.51US$0.87n/a3
Dec ’25US$1.41
US$0.99
-29.41%
22.00%US$1.28US$0.75n/a3
Nov ’25US$0.91
US$0.99
+9.00%
22.00%US$1.28US$0.75US$1.973
Oct ’25US$0.87
US$0.99
+13.76%
22.00%US$1.28US$0.75n/a3
Sep ’25n/a
US$0.99
0%
22.00%US$1.28US$0.75US$1.513
Aug ’25n/a
US$0.84
0%
12.00%US$0.94US$0.74US$1.512
Jul ’25US$0.66
US$0.72
+9.67%
27.27%US$0.92US$0.53n/a2
Jun ’25US$0.84
US$0.72
-13.51%
27.27%US$0.92US$0.53US$1.442
May ’25US$0.76
US$0.72
-4.76%
27.27%US$0.92US$0.53US$1.442
US$3.24
Fair Value
47.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/12 16:51
End of Day Share Price 2026/04/24 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mesoblast Limited is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Stuart RobertsBell Potter
Matthew PriorBofA Global Research